Takeover excluded: Fresenius renounces Akorn
The Bad Homburger Medizinkinzernern Fresenius SE wants to break the takeover agreement of the US-American group Akorn Inc., manufacturer of cancer generics. Akorn did not fulfill the requirements of the merger agreement. With that, the 4.4 billion deal is unlikely to materialize. Because the US company insists on compliance with the secrecy clause, said the spokesman of Fresenius, Matthias Link, but no specific reasons.